BIODELPHIS THERAPEUTICS
LIVE

Serial Number

79453338

Owner

Biodelphis Therapeutics SA

Attorney

Jaron Bentley

Filing Date

Mar 27, 2026

Add to watchlist:

No watchlists yet
View on USPTO

BIODELPHIS THERAPEUTICS Trademark

Serial Number: 79453338

BIODELPHIS THERAPEUTICS is a trademark filed by Biodelphis Therapeutics SA on March 27, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Biodelphis Therapeutics SA

c/o Aaron Simone Petruzzella

Entity Type: 33

Trademark Details

Filing Date

March 27, 2026

Registration Date

Not Registered

Goods & Services

Retail or wholesale services for pharmaceutical, biotechnological and veterinary preparations as well as for medical supplies; all of the foregoing, with the exception of retail, wholesale or consulting services concerning diagnostic medical devices, genetic testing reagents or equipment intended for neurological research or diagnosis

Processing and manufacturing of biochemical and pharmaceutical products for third parties and related consulting services; custom manufacturing of pharmaceutical products to order and according to a client's specifications; all of the foregoing, with the exception of services involving DNA sequencing, gene cloning, genetic modification of cells or nanotechnological processes intended for administering therapeutic agents

Research and development for the pharmaceutical industry; research and development in the field of biotechnology; biotechnology research; research in biotechnology; biomedical research services; pharmaceutical research and development services; medical research services; scientific research services for medical purposes; scientific and technological services, as well as related research and development services; all of the above, excluding medical or clinical research in the field of genetic or neurological diseases, as well as services related to genetic engineering, DNA manipulation, or drug delivery using nanotechnology

Pharmaceutical preparations, namely antibody-peptide inhibitor conjugates intended for use in oncology as well as for the treatment of osteoporosis and autoimmune diseases; Dietary supplements for humans; all of the foregoing, excluding pharmaceutical or biotechnological preparations intended for genetic or neurological diagnosis or treatment, or involving genetic engineering, DNA manipulation, or drug delivery systems based on nanotechnology

Filing History

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 6, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 6, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 6, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 6, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 6, 2026 COAR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 25, 2026 RFCR
NON-FINAL ACTION WRITTEN
Jul 24, 2026 CNRT
ASSIGNED TO EXAMINER
Jul 24, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 23, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 23, 2026 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 17, 2026 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 2, 2026 REPR